Fenwick & West represented Invenra Inc. in its expanded collaboration with Exelixis, Inc.
Exelixis (Nasdaq: EXEL) and Invenra had entered into a collaboration on May 2, 2018, to discover and develop multispecific antibodies through the use of Invenra’s B-BodyTMtechnology platform.
The new collaboration will continue to use the Invenra antibody discovery capabilities to generate additional biologics-based programs.
Invenra Inc., is a biotechnology company focused on the discovery and development of multispecific antibodies for immuno-oncology and autoimmunity.
Exelixis, Inc. operates as a development-stage biotechnology company focuses on discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases.
The Fenwick transaction team included technology transactions partner Stefano Quintini (Picture) and licensing attorney Amy Manning.
Law Firms: Fenwick & West LLP;
Clients: Invenra Inc.;